NEW YORK, June 9 (GenomeWeb News) - Alnylam Pharmaceutials has licensed its short interfering RNA technology patents to Ambion to provide research products and services, the companies said yesterday.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.